Concise Prescribing Info
Severe refractory eosinophilic asthma.
Dosage/Direction for Use
Adult : SC As add-on maintenance therapy: 30 mg once every 4 weeks for the 1st 3 doses then once every 8 weeks.
Dosage Details
Eosinophilic asthma
Adult: As add-on maintenance therapy in patients with severe refractory cases: 30 mg once every 4 weeks for the 1st 3 doses then once every 8 weeks thereafter. Continue therapy according to patient tolerability and safety.
Child: ≥12 years Same as adult dose.
Treatment of acute asthma exacerbations, status asthmaticus and acute bronchospasm.
Special Precautions
Patient with parasitic or helminth infection. Children. Pregnancy and lactation.
Adverse Reactions
Significant: Hypersensitivity reactions including anaphylaxis (e.g. urticaria, papular urticaria, rash).
General disorders and admin site conditions: Pyrexia.
Injury, poisoning and procedural complications: Injection site reaction (e.g. pain, erythema, pruritus, papule).
Nervous system disorders: Headache.
Respiratory, thoracic and mediastinal disorders: Pharyngitis.
Monitor pulmonary function tests (e.g. peak flow), signs of infection and anaphylaxis/hypersensitivity reactions during and after administration.
Description: Benralizumab is a humanised, afucosylated, monoclonal antibody (IgG1 kappa) which selectively binds to the α subunit of interleukin-5 (IL-5) receptor on eosinophils (cell type associated with inflammation) and basophils leading to apoptosis and depletion of eosinophils and basophils.
Absorption: Bioavailability: Approx 58%.
Distribution: Crosses the placenta, enters breast milk. Volume of distribution: 3.2 L (central); 2.5 L (peripheral).
Metabolism: Undergoes proteolytic degradation via enzymes in the body and not restricted to hepatic tissue.
Excretion: Elimination half-life: Approx 15 days.
Store between 2-8°C. Do not freeze. Protect from light.
ATC Classification
R03DX10 - benralizumab ; Belongs to the class of other systemic drugs used in the treatment of obstructive airway diseases.
Disclaimer: This information is independently developed by MIMS based on Benralizumab from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in